UNSPSC 51283932: Sulfanilamide or sulphanilamide

This classification denotes a sulfonamide anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 21240MF57M. European Medicines Agency schedules Sulfanilamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10718MIG. Sulfanilamide generally arises in the molecular formula C6H8N2O2S.

The term SULFANILAMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13, no. 12, 1959, list 3.) SULFANILAMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Sulfanilamide or sulphanilamide bears US NLM identifiers UMLS ID C0038702 and NCI Concept Code C47738. SMILES: S(=O)(=O)(N)C1CCC(N)CC1.

UNSPSC 51283932 Sulfanilamide or sulphanilamide is a Commodity code that does not reflect the pharmaceutical procurement activity currently being solicited under it by state and local governments. Recent opportunities tagged to this code involve naloxone, medical and first aid supplies, generic multi-source pharmaceuticals, and over-the-counter products—none of which are sulfanilamide or directly related sulfonamide antibiotics. The mismatch suggests a classification inconsistency in how some issuing bodies tag pharmaceutical procurement rather than active market demand for the specific antibiotic named in the code.

State and local health agencies, fire departments, and cooperative purchasing alliances have posted opportunities in this classification across Florida, Texas, Minnesota, and Oregon. Seminole County, Florida issued an IFB in June 2026 to procure naloxone and drug deactivation systems; the City of Tampa posted an IFB in March 2026 for medical and first aid supplies for the Tampa Fire Department with an estimated contract value of $700,000 and a small local business enterprise set-aside; the Texas Health and Human Services Commission issued an RFI in April 2026 regarding direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with responses due March 26, 2026. The MMCAP procurement serves state and local government facilities across multiple participating jurisdictions. The code shows little relevant recent activity aligned to its nominal scope and warrants clarification with issuing bodies before pursuing opportunities under it.